Details for New Drug Application (NDA): 020841
✉ Email this page to a colleague
The generic ingredient in LOTEMAX is loteprednol etabonate. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for 020841
| Tradename: | LOTEMAX |
| Applicant: | Pharmos |
| Ingredient: | loteprednol etabonate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020841
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.5% | ||||
| Approval Date: | Mar 9, 1998 | TE: | RLD: | No | |||||
Expired US Patents for NDA 020841
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | 4,996,335 | ⤷ Start Trial |
| Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | 5,540,930 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
